Hi, we've made some changes

Alizyme(AZM)

Sector:

Pharmaceuticals & Biotechnology

Index:

FTSE Small Cap

Market Cap

£39.80m

Change Today

Price Down-0.50p

Share Price

18.00p

Latest ShareCast News

TechMARK movers: Alizyme jumps on licence deal

Date: Friday 27 Jun 2008

Alizyme rallied on news that it could net up to €42.75m after it granted an exclusive licence to Norgine for the rights to market Colal-Pred, used to treat ulcerative colitis, in Europe, South Africa, Australia and New Zealand.

Alizyme Regulatory News

Annual Information Update 01-Jul-2008 11:09 RNS
ALIZYME LICENSES COLAL-PRED? 27-Jun-2008 07:00 RNS
Result of AGM 24-Jun-2008 11:48 RNS
Presentation at Conference 20-Jun-2008 09:02 RNS
ALIZYME AT THE 2008 BIO INTER 12-Jun-2008 10:00 RNS

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alizyme Market Data

Currency UK Pounds
Share Price 18.00p Price Down
Change Today -0.50p
52 Week High 98.50p
52 Week Low 17.25p
Volume 242,660
Shares Issued 221.10m
Market Cap £39.80m
Beta 0.65
RiskGrade 365

Alizyme Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
63.58% below the market average63.58% below the market average63.58% below the market average63.58% below the market average63.58% below the market average
87.95% below the sector average87.95% below the sector average87.95% below the sector average87.95% below the sector average87.95% below the sector average
Price Trend
93.89% below the market average93.89% below the market average93.89% below the market average93.89% below the market average93.89% below the market average
82.42% below the sector average82.42% below the sector average82.42% below the sector average82.42% below the sector average82.42% below the sector average
Income Not Available
Growth
31.42% below the market average31.42% below the market average31.42% below the market average31.42% below the market average31.42% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alizyme Dividends

No dividends found

Trades for 04-Jul-2008

Time Volume / Share Price
16:35 2,071 @ 18.00p
16:06 25,000 @ 17.50p
16:06 25,000 @ 17.75p
15:31 1,644 @ 17.75p
14:51 4,500 @ 17.96p

Alizyme Key Personnel

CEO Tim P McCarthy
Chair Brian Richards
Finance Director David Campbell

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).